Association of triglycerides to high-density lipoprotein cholesterol ratio to identify future prediabetes and type 2 diabetes mellitus: over one-decade follow-up in the Iranian population.

Dysglycemia High-density lipoprotein cholesterol Prediabetes Ratio Triglycerides Type 2 diabetes mellitus

Journal

Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958

Informations de publication

Date de publication:
02 Feb 2023
Historique:
received: 29 08 2022
accepted: 27 01 2023
entrez: 3 2 2023
pubmed: 4 2 2023
medline: 4 2 2023
Statut: epublish

Résumé

To determine the association between triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) for identifying subjects at risk of incident prediabetes and type 2 diabetes mellitus (T2DM). In 5064 subjects (men = 2247) aged ≥ 20 years, using Cox proportional hazards regression analyses, the associations of TG/HDL-C with incident prediabetes and T2DM were examined among normoglycemic men and women. Furthermore, the association of this lipid ratio with incident T2DM was also assessed among prediabetic subjects (n = 1414). The multivariable analyses were adjusted for age, body mass index, waist-to-height ratio, wrist circumference, systolic blood pressure, family history of T2DM, education level, history of cardiovascular diseases, and fasting plasma glucose (FPG). During a median follow-up of 11.2 years, 2140 new cases of prediabetes (men = 1070) and 360 incident T2DM (men = 152) were identified among normoglycemic individuals. In the prediabetic population, 574 new cases of T2DM (men = 252) were developed. Among the whole population, compared to the first quartile (reference), higher quartiles of TG/HDL-C were significantly associated with higher risks of incident prediabetes and T2DM among normoglycemic individuals and incident T2DM in the prediabetic population (all P for trend < 0.001). The corresponding hazard ratios (HRs) and 95% confidence intervals (CIs) for the fourth quartiles were 1.37(1.20-1.58), 1.92(1.34-2.75), and 1.57(1.22-2.01), respectively. The sex-stratified analyses demonstrated similar significant associations in both sexes; however, TG/HDL-C lost its association with incident T2DM among prediabetic men. Among the normoglycemic population, 1 unit increase in TG/HDL-C was significantly associated with incident prediabetes and T2DM [1.02(1.00-1.03) and 1.06(1.03-1.08), respectively]. The corresponding value for incident T2DM in prediabetic individuals was 1.01(1.00-1.03). In a subgroup population having insulin data (n = 2897), the associations between TG/HDL-C and incident prediabetes and T2DM among normoglycemic individuals generally persisted even after replacing FPG with an index of insulin resistance (IR), i.e., homeostasis model assessment of IR (HOMA-IR) in the adjusted model. In conclusion, in the normoglycemic population, the increasing value of TG/HDL-C was unfavorably associated with incident prediabetes and T2DM, especially among women. Similarly, TG/HDL-C was associated with incident T2DM in prediabetic individuals. Generally, we found that the correlation between TG/HDL-C and different states of dysglycemia is independent of HOMA-IR.

Sections du résumé

BACKGROUND BACKGROUND
To determine the association between triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) for identifying subjects at risk of incident prediabetes and type 2 diabetes mellitus (T2DM).
METHODS METHODS
In 5064 subjects (men = 2247) aged ≥ 20 years, using Cox proportional hazards regression analyses, the associations of TG/HDL-C with incident prediabetes and T2DM were examined among normoglycemic men and women. Furthermore, the association of this lipid ratio with incident T2DM was also assessed among prediabetic subjects (n = 1414). The multivariable analyses were adjusted for age, body mass index, waist-to-height ratio, wrist circumference, systolic blood pressure, family history of T2DM, education level, history of cardiovascular diseases, and fasting plasma glucose (FPG).
RESULTS RESULTS
During a median follow-up of 11.2 years, 2140 new cases of prediabetes (men = 1070) and 360 incident T2DM (men = 152) were identified among normoglycemic individuals. In the prediabetic population, 574 new cases of T2DM (men = 252) were developed. Among the whole population, compared to the first quartile (reference), higher quartiles of TG/HDL-C were significantly associated with higher risks of incident prediabetes and T2DM among normoglycemic individuals and incident T2DM in the prediabetic population (all P for trend < 0.001). The corresponding hazard ratios (HRs) and 95% confidence intervals (CIs) for the fourth quartiles were 1.37(1.20-1.58), 1.92(1.34-2.75), and 1.57(1.22-2.01), respectively. The sex-stratified analyses demonstrated similar significant associations in both sexes; however, TG/HDL-C lost its association with incident T2DM among prediabetic men. Among the normoglycemic population, 1 unit increase in TG/HDL-C was significantly associated with incident prediabetes and T2DM [1.02(1.00-1.03) and 1.06(1.03-1.08), respectively]. The corresponding value for incident T2DM in prediabetic individuals was 1.01(1.00-1.03). In a subgroup population having insulin data (n = 2897), the associations between TG/HDL-C and incident prediabetes and T2DM among normoglycemic individuals generally persisted even after replacing FPG with an index of insulin resistance (IR), i.e., homeostasis model assessment of IR (HOMA-IR) in the adjusted model.
CONCLUSIONS CONCLUSIONS
In conclusion, in the normoglycemic population, the increasing value of TG/HDL-C was unfavorably associated with incident prediabetes and T2DM, especially among women. Similarly, TG/HDL-C was associated with incident T2DM in prediabetic individuals. Generally, we found that the correlation between TG/HDL-C and different states of dysglycemia is independent of HOMA-IR.

Identifiants

pubmed: 36732786
doi: 10.1186/s13098-023-00988-0
pii: 10.1186/s13098-023-00988-0
pmc: PMC9893691
doi:

Types de publication

Journal Article

Langues

eng

Pagination

13

Subventions

Organisme : Shahid Beheshti University of Medical Sciences
ID : No.2-43002896
Organisme : The National Research Council of the Islamic Republic of Iran
ID : 121

Informations de copyright

© 2023. The Author(s).

Références

PLoS One. 2019 Jan 31;14(1):e0211070
pubmed: 30703129
J Diabetes Complications. 2019 Feb;33(2):118-122
pubmed: 30522790
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
J Pediatr Endocrinol Metab. 2020 May 24;33(6):777-784
pubmed: 32447329
J Clin Endocrinol Metab. 2013 Feb;98(2):777-84
pubmed: 23341488
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Front Endocrinol (Lausanne). 2022 Jul 18;13:947157
pubmed: 35923622
Horm Metab Res. 2017 Jul;49(7):542-549
pubmed: 28597452
Am J Cardiol. 2012 Jun 15;109(12):1749-53
pubmed: 22449634
Diabet Med. 2017 Jan;34(1):69-78
pubmed: 26606421
Endocrinol Metab Clin North Am. 2021 Sep;50(3):369-385
pubmed: 34399951
Acta Diabetol. 2018 Oct;55(10):1067-1074
pubmed: 30066042
Lipids Health Dis. 2016 Jun 07;15:104
pubmed: 27267043
Eur J Public Health. 2011 Oct;21(5):554-9
pubmed: 20534689
J Cardiol. 2018 Jan;71(1):8-9
pubmed: 29033056
Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):318-329
pubmed: 34953633
Nutr Metab Cardiovasc Dis. 2022 Aug;32(8):1872-1879
pubmed: 35753859
Diabetes Care. 2015 Apr;38(4):628-36
pubmed: 25592196
J Clin Hypertens (Greenwich). 2010 Jan;12(1):51-8
pubmed: 20047632
Diabet Med. 2017 Feb;34(2):245-252
pubmed: 26996519
Diabetes Res Clin Pract. 2020 May;163:108150
pubmed: 32305400
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Int J Endocrinol. 2021 Jul 08;2021:9949579
pubmed: 34306073
PLoS One. 2014 Jul 16;9(7):e102563
pubmed: 25029368
Cardiovasc Diabetol. 2011 Oct 17;10:93
pubmed: 22004541
Diabetes Care. 2008 Jan;31(1):96-8
pubmed: 17921357
J Diabetes Complications. 2022 Jul;36(7):108231
pubmed: 35718599
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Cardiovasc Diabetol. 2021 Sep 9;20(1):183
pubmed: 34503545
Diabetes Metab Res Rev. 2016 Sep;32(6):572-80
pubmed: 26663847
J Diabetes. 2019 Mar;11(3):183-192
pubmed: 30091266
Pathophysiology. 2022 Jul 17;29(3):374-382
pubmed: 35893599
Lipids Health Dis. 2010 Aug 17;9:85
pubmed: 20712907
Front Pharmacol. 2015 Oct 31;6:258
pubmed: 26582989
Lipids Health Dis. 2020 Jun 2;19(1):121
pubmed: 32487177
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
Acta Diabetol. 2015 Oct;52(5):905-15
pubmed: 25794879
Lipids Health Dis. 2019 Jun 1;18(1):130
pubmed: 31153374

Auteurs

Maryam Tohidi (M)

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O.Box 19395-4763, Tehran, Islamic Republic of Iran.

Samaneh Asgari (S)

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O.Box 19395-4763, Tehran, Islamic Republic of Iran.

Abdolreza Chary (A)

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O.Box 19395-4763, Tehran, Islamic Republic of Iran.

Siavash Safiee (S)

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O.Box 19395-4763, Tehran, Islamic Republic of Iran.

Fereidoun Azizi (F)

Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Farzad Hadaegh (F)

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O.Box 19395-4763, Tehran, Islamic Republic of Iran. fzhadaegh@endocrine.ac.ir.

Classifications MeSH